Fujian Provincial Hospital
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1937-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://fjsl.com.cn/
Integral Single-cell Landscape of Immunological Hallmarks for Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06846021
- Locations
- 🇨🇳
Orthopedic Outpatient Room, Fuzhou, China
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
- Conditions
- Locally Advanced Pancreatic CancerMetastatic Pancreatic Cancer
- Interventions
- Drug: Anlotinib combined with Sintilimab
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06761027
- Locations
- 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Comparative Study on Surgical Approaches for Elderly Femoral Neck Fractures
- Conditions
- FunctionPain
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT06760949
- Locations
- 🇨🇳
Fujian Provincial Hospital Trauma Center, Fuzhou, Fujian, China
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
- Conditions
- Non-Alcoholic Fatty Liver Disease
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06717828
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: a Prospective, Single-arm, Phase II Clinical Study
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06643208
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
- Conditions
- Hepatocellular Carcinoma Non-resectable
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06643533
Real-world Study of Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Combination Product: TACE, Lenvatinib, combined with Tislelizumab group
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06602011
- Locations
- 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
Effects of Esketamine on Postoperative Behavioral Changes in Children Undergoing Tonsillectomy and/or Adenoidectomy
- Conditions
- Behavior Problem
- Interventions
- Drug: normal saline
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT06579937
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
Dexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum
- Conditions
- Laparoscopic Cholecystectomy
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06575179
- Locations
- 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
Neoadjuvant Triple Therapy for Resectable HCC
- Conditions
- Resectable Hepatocellular Carcinoma
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06569498
- Locations
- 🇨🇳
Fujian provincial hospital, Fuzhou, Fujian, China
🇨🇳First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China